Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10566957
Filing Date		2006-01-27
First Named Inventor Kuroo		da
Art Unit		
Examiner Name		
Attornov Docket Numb		NAMP120LIS

				LXaiii	iiioi ita	iiie						
				Attorn	ey Doc	ket Numbe	er	NANP129US				
												Т
					U.S.	PATENTS				Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue E	ssue Date Name of Patentee or Applicant Re			Relev	ages,Columns,Lines where Relevant Passages or Relevant igures Appear			
	1											
If you wish	h to a	dd additional U.S. Pater	nt citation	n inform	ation pl	lease click t	the /	Add button.		Add		_
			U.S.P.	ATENT	APPLI	CATION P	JBL	ICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	Releva			s,Columns,Lines where vant Passages or Relevant es Appear				
	1	20030064394		2003-0	4-03	Ohtake et	al					
If you wish	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n informatio	on pl	ease click the Ad	d butto	n. Add		
				FOREIG	SN PAT	TENT DOC	UME	NTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4	Publicatio Date	n	Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	+-
	1	0029603	wo			2000-05-2	5	Neose Technologi	es			
	2	0068418	wo			2000-11-1	6	Medical Research Council				
If you wish	h to a	dd additional Foreign P	atent Do	cument	citation	information	n ple	ease click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE	DOC	UMENTS		Remove		_

# | Application Number | 10569957 | Fing Date | 2006-01-27 | Fing Date | 2006-01-27 | Fing Date | 2006-01-27 | First Numed Inventor | Kuroda | Art Unit | Examiner Name | Attorney Docket Number | NAMP129US

Include name of the author (in CARITAL LETTERS) title of the article (when appropriate) title of the item

Examiner Initials*	Cite No	(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	DELUCA et al. Kinetos of the Firefly Luciferase Catalyzed Reactions, Boothemstry, Vol 13, PP. 921-925, 1974	
	2	BAUTISTA et al., Adenosine Triphosphate Bioluminescence as a Method to Determine Microbial Levels in Scald and Chill Tanks at a Pourity Abetiolic, Poulity Science, Vol. 73, PP. 1673-1678, 1994	
	3	SPENCER et al., Preparedness and Response to Bioterrorism, Journal of Infection, Vol. 43, PP. 104-110, 2001	
	4	CHITTOCK et al, Kinetic Aspects of ATP Amplification Reactions, Analytical Biochemistry, Vol. 255, PP. 120-126, 1998	
	5	NEUHARD et al., Purines and Pyrimidnes, Biosynthesis and Conversions of Nucleotides, PP. 445-473, 1987	
	6	NEIDHARDT, Chemical Composition and Escherichia Coll, Part I, Molecular Architecture and Assembly of Cell Parts, PP. 3-6, 1987	
	7	BERT et al, Muti-Resistant Pseudomonas Aerugnosa Outbreak Associated with Contaminated Tap Water in a Neurosurgery Intensive Care Unit, Journal of Hospital Infection, Vol. 39, PP. 53-62, 1998	
	8	OLSSON et al, Extraction and Determination of Adenosine 5-Triphosphate in Bovine Milk by the Firefly Luc/ferase Assay, Biotechnology and Applied Bochemistry, Vol. 8, PP. 361-369, 1986	
	9	SHIMCMURA et al, Proceedings of Annual Conference of Society of Chemical Engineers, Vol. 66, P 647, 2001	
	10	SATOH et al, ATP Amplification for Ultrasensitive Bioluminescence Assay, Detection of a Single Bacterial Cell, Bioscience, Biotechnology, Biochemistry, Vol. 68, PP. 1216-1220, 2004	

	Application Number		10566957	
INFORMATION DIGGS COURT	Filing Date		2006-01-27	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Kuro		da	
(Not for submission under 37 CFR 1.99)	Art Unit			
(Not for Submission under or or it issay	Examiner Name			
	Attorney Docket Number		NANP129US	

Examiner Signature		Date Considered	
*EXAMINER: Initial if	ance with MPEP 609	Draw line through a	

If you wish to add additional non-patent literature document citation information please click the Add button Add

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kits Codes of USPTO Peter Documents at wave USPTO GOV or MPEP 90.04. 2 Enter of this that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Largeriese patert documents are noticed in oil by an of the simple of the Emperor must preced the serial number of the patent document. See the serial number of the patent document. The preceding the

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit

Application Number		10566957
Filing Date		2006-01-27
First Named Inventor	Kuroo	da
Art Unit		
Examiner Name		
Attorney Docket Number	er .	NANP129US

### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.9	8 to make	the ap	propriate	selection(s):
---------------	----------	---------	-----------	--------	-----------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eVI).

### ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Greg Turocy/	Date (YYYY-MM-DD)	2006-07-27
Name/Print	Gregory Turpcy	Registration Number	36952

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.